Mapp Biopharmaceutical
Mapp Biopharmaceutical is a San Diego-based, founder-owned clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for high-consequence infectious diseases (Ebola, Marburg, Nipah) and biodefense threats, funded primarily through U.S. federal BARDA and ASPR contracts.
- Company typePrivate
- Founded2003
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mapp Biopharmaceutical does
Mapp Biopharmaceutical, Inc. is a privately held, founder-owned clinical-stage biopharmaceutical company founded in 2003 in San Diego, California by Drs. Kevin Whaley and Larry Zeitlin. The company develops monoclonal antibody therapeutics targeting high-consequence infectious diseases and biodefense threats, with a current pipeline spanning multiple ebolavirus species (MBP134, a broad-spectrum cocktail), Marburg virus (MBP091), Nipah virus, Botulinum Neurotoxin, Junin virus, ricin, and other priority pathogens. Its core technology platform uses affinity maturation to engineer antibodies with broadened neutralizing activity across viral species and strains, enabling coverage that single-target therapeutics cannot match.
Mapp's business model is government-countermeasure procurement-driven rather than commercial. Revenue flows primarily from U.S. federal contracts awarded by BARDA and ASPR for advanced development, Phase 1 clinical trials, and potential purchase of investigational therapeutics for the Strategic National Stockpile. Disclosed federal contract value exceeds $141 million across three awards (2018, 2019, 2022), with options bringing headline value to roughly $204 million. Products are investigational and provided through expanded access or WHO-coordinated clinical trials in outbreak settings; commercial pricing does not exist and the products, once procured, are owned by the U.S. government. Distribution occurs exclusively through government stockpiling, clinical-trial deployment, and emergency-use mechanisms, with no traditional pharmaceutical sales or marketing infrastructure.
The customer base is concentrated almost entirely within U.S. federal health and biodefense agencies (BARDA, ASPR, HHS), with operational reach extending into outbreak-affected geographies (DRC, India, Bangladesh) via partnerships with WHO, the University of Oxford, Vanderbilt University Medical Center, Albert Einstein College of Medicine, and Gilead Sciences. The company maintains a small employee base of 11-50 and has no institutional VC/PE investors, remaining fully owned by its two scientist founders. Its competitive position rests on proprietary antibody-engineering know-how, exclusive survivor-derived antibody licenses, deep federal-agency relationships, and the capital-intensive nature of BSL-3/4 countermeasure development that discourages larger commercial pharma participation.
Mapp Biopharmaceutical firmographics
Firmographics- Name
- Mapp Biopharmaceutical
- Legal name
- Mapp Biopharmaceutical, Inc.
- Website
- https://mappbio.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mapp Biopharmaceutical is a San Diego-based, founder-owned clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for high-consequence infectious diseases (Ebola, Marburg, Nipah) and biodefense threats, funded primarily through U.S. federal BARDA and ASPR contracts.
- Ownership category
- akta.pro rank
Mapp Biopharmaceutical industry classification
Industry- Product category
- Infectious Disease Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
- akta.pro secondary industry
- Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF)
Keywords
Where Mapp Biopharmaceutical is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Mapp Biopharmaceutical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure
Revenue model
- Government Contracts and BARDA Funding: Mapp Biopharmaceutical generates revenue primarily through government contracts with BARDA, ASPR, and other federal agencies. These contracts fund advanced development and procurement of medical countermeasures for biodefense and emerging infectious diseases. Contracts include advanced research and development funding, Phase 1 clinical trial support, and potential purchase agreements for successful therapeutics.
- U.S. Government Procurement: The U.S. government (Department of Health and Human Services, ASPR, BARDA) procures Mapp's investigational therapeutics for the Strategic National Stockpile and emergency response. Existing doses are owned by the U.S. government.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
Mapp Biopharmaceutical product offering
Product offeringCore offering
Mapp Biopharmaceutical develops investigational monoclonal antibody therapeutics for the prevention and treatment of infectious diseases, with emphasis on filoviruses (Ebola, Marburg, Bundibugyo), Nipah virus, and other high-consequence pathogens as well as biodefense threats (botulinum neurotoxin, ricin). The company's products are advanced through Phase 1 clinical trials and procured primarily through U.S. government contracts with BARDA and ASPR, with deployment via the Strategic National Stockpile, WHO-coordinated outbreak clinical trials, and expanded access programs.
Product overview
Mapp Biopharmaceutical develops a portfolio of monoclonal antibody therapeutics for infectious diseases, focusing on unmet needs in global health and biodefense. The core products include MBP134 (broad-spectrum anti-filovirus cocktail targeting multiple Ebola species), MBP091 (pan-Marburg therapeutic), ZMapp (Ebola virus treatment), Nipah monoclonal antibody, Botulinum Neurotoxin therapeutic, and earlier-stage candidates for hantavirus, Crimean Congo Hemorrhagic Fever virus, and ricin. The company was founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin and maintains collaborations with BARDA, NIH, and academic partners.
Differentiator
Problem solved
Functional benefit
Products and services
- MBP134 Investigational monoclonal antibody cocktail targeting multiple ebolaviruses including Zaire, Sudan, Bundibugyo, Reston, Tai Forest, and Bombali species; designed for broad-spectrum treatment of Ebola virus disease.
- MBP091 Single human monoclonal antibody developed as a pan-Marburg virus therapeutic for treatment of hemorrhagic fevers caused by Marburg and closely related Ravn virus; isolated at Vanderbilt University Medical Center from a Marburg survivor.
- ZMapp Cocktail of mouse-human chimeric monoclonal antibodies for Ebola virus (Zaire ebolavirus); granted Orphan Medicinal Product Designation by EMA and Fast Track Status by FDA.
- Nipah Monoclonal Antibody Novel Nipah monoclonal antibody undergoing human clinical trials in India and Bangladesh; designed to offer immediate post-exposure protection against Nipah virus.
- Botulinum Neurotoxin Therapeutic Next-generation monoclonal antibody-based therapeutic for Botulinum Neurotoxin (BoNT) being developed in partnership with BARDA for biodefense preparedness.
- Ricin Antibody Monoclonal antibodies providing protection against ricin toxin, including plant-based expression of partially humanized neutralizing antibodies, for biodefense applications.
- Junin Virus Antibody Humanized monoclonal antibody therapeutic developed for Argentine hemorrhagic fever caused by Junin virus.
Companies that use Mapp Biopharmaceutical
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
Mapp Biopharmaceutical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Mapp Biopharmaceutical partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- University of OxfordcoreUniversity of Oxford is leading clinical trials of MBP134 and Gilead antivirals in the DRC Ebola outbreak, working with Congolese and Ugandan governments under WHO sponsorship. Oxford is also developing Bundibugyo vaccine candidates in collaboration with the Serum Institute of India.
- Gilead SciencesminorGilead Sciences is donating doses of remdesivir and obeldesivir for WHO-sponsored clinical trials in DRC, testing Mapp's MBP134 alongside Gilead antivirals to evaluate individual and combination therapy approaches for Bundibugyo ebolavirus.
- The Alliance for International Medical Action (ALIMA)minorALIMA is partnering with DRC's National Institute for Biomedical Research and Oxford University in WHO-sponsored clinical trials of Mapp and Gilead therapeutics against Bundibugyo ebolavirus.
- Democratic Republic of Congo National Institute for Biomedical ResearchcoreDRC's National Institute for Biomedical Research is collaborating with WHO, Oxford University, and ALIMA to conduct clinical trials of Mapp's MBP134 and Gilead's antivirals against the Bundibugyo ebolavirus outbreak.
- Vanderbilt University Medical CentercoreDr. James Crowe's laboratory at Vanderbilt isolated the MBP091 monoclonal antibody from a survivor of Marburg virus infection. The antibody was subsequently licensed by Mapp for development as a pan-Marburg therapeutic.
- Adimab LLCcoreCollaboration with Adimab LLC led by Dr. Laura Walker for identification of monoclonal antibodies from survivors of the 2013-2016 Ebola outbreak. Mapp obtained exclusive license to develop and commercialize these antibodies from Adimab and Albert Einstein College of Medicine. The partnership utilized Adimab's antibody discovery platform.
- Albert Einstein College of MedicinecoreAcademic partner in the antibody discovery collaboration. Part of NIAID-supported Centers of Excellence for Translational Research at four institutions. Mapp obtained exclusive license to develop and commercialize antibodies from Adimab and Einstein.
- National Institute of Allergy and Infectious Diseases (NIAID)coreNIAID-supported Centers of Excellence for Translational Research at multiple institutions (Albert Einstein College of Medicine, Public Health Agency of Canada, University of Texas Medical Branch at Galveston, and USAMRIID) collaborated on antibody identification. NIAID funding supported research through grants (U19AI109711, U19AI109762, HHSN2722011000221).
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
Mapp Biopharmaceutical competitors and assessment
Company assessmentDirect peers
- Vir Biotechnology: Clinical-stage immunology company developing monoclonal antibody therapeutics for serious infectious diseases, including influenza, hepatitis B, and coronaviruses. Directly comparable to Mapp in antibody platform, infectious disease focus, and pre-commercial clinical development stage.
- BioCryst Pharmaceuticals: Commercial-stage biotech developing therapeutics for rare infectious diseases and hereditary angioedema. Comparable business model targeting underserved infectious disease indications with government stockpiling and small patient populations.
Broad incumbents
- Regeneron Pharmaceuticals: Large biotech with a deep monoclonal antibody platform that developed REGN-EB3 (Inmazeb), an approved Ebola therapeutic that directly competes with Mapp's ZMapp/MBP134 in the filovirus treatment market. Comparable antibody technology and government countermeasure positioning.
- Emergent BioSolutions: Specialty biopharmaceutical company focused on biodefense and public health preparedness products, including vaccines and antibody therapeutics for anthrax, smallpox, and botulinum. Comparable biodefense countermeasure business with strong U.S. government customer base.
- Gilead Sciences: Large antiviral pharmaceutical company and current Mapp partner donating remdesivir/obeldesivir for combination trials in the Bundibugyo outbreak. Overlapping infectious disease franchise and government countermeasure positioning.
- Merck & Co. Large pharmaceutical company with a major vaccines and infectious disease franchise, including Ervebo Ebola vaccine and partnerships with government health authorities on outbreak response. Comparable global infectious disease countermeasure footprint.
Emerging players
- Ridgeback Biotherapeutics: Late-stage biopharmaceutical company developing therapeutics for infectious diseases, including the approved oral antiviral molnupiravir for COVID-19 and Ebola antibody programs. Comparable emerging infectious disease biotech with government-aligned business model.
- SAB Biotherapeutics: Clinical-stage biopharmaceutical company developing polyclonal antibody therapeutics for infectious diseases and immune disorders. Comparable antibody platform focus and government countermeasure contracts.
- Leaf Biopharmaceutical: Biopharmaceutical company that in-licensed Mapp's filovirus monoclonal antibody technology in 2014 for commercialization. Closely connected emerging player in the same therapeutic area.
- CureVac: Clinical-stage biopharmaceutical company developing mRNA-based vaccines and therapeutics for infectious diseases and oncology. Comparable emerging biotech with government countermeasure contracts and infectious disease focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Mapp Biopharmaceutical social profiles
Digital presenceMapp Biopharmaceutical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mapp Biopharmaceutical leadership team
Management profileNumber of profiles
Profiles5 records
Mapp Biopharmaceutical funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mapp Biopharmaceutical M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mapp Biopharmaceutical
What does Mapp Biopharmaceutical do?
Mapp Biopharmaceutical develops investigational monoclonal antibody therapeutics for the prevention and treatment of infectious diseases, with emphasis on filoviruses (Ebola, Marburg, Bundibugyo), Nipah virus, and other high-consequence pathogens as well as biodefense threats (botulinum neurotoxin, ricin). The company's products are advanced through Phase 1 clinical trials and procured primarily through U.S. government contracts with BARDA and ASPR, with deployment via the Strategic National Stockpile, WHO-coordinated outbreak clinical trials, and expanded access programs.
Is Mapp Biopharmaceutical a public or private company?
Mapp Biopharmaceutical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Mapp Biopharmaceutical founded?
Mapp Biopharmaceutical was founded in 2003. It employs 11 to 50 people.
Where is Mapp Biopharmaceutical based?
Mapp Biopharmaceutical is headquartered in San Diego, United States, in the North America region.
How does Mapp Biopharmaceutical make money?
Two revenue lines are on record. Government Contracts and BARDA Funding is the primary driver. The others are U.S. Government Procurement.
Who are Mapp Biopharmaceutical's main competitors?
Direct peers on record are Vir Biotechnology and BioCryst Pharmaceuticals. Broad incumbents are Regeneron Pharmaceuticals, Emergent BioSolutions, Gilead Sciences and Merck & Co.. Emerging players are Ridgeback Biotherapeutics, SAB Biotherapeutics, Leaf Biopharmaceutical and CureVac.
Does Mapp Biopharmaceutical have an API?
No public API is recorded for Mapp Biopharmaceutical.
What industry is Mapp Biopharmaceutical in?
Mapp Biopharmaceutical's product category is Infectious Disease Therapeutics. Its primary akta.pro industry code is HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine), with a secondary code of HLAIAEAF, Pandemic Preparedness & Rapid-Response Vaccines. Its NAICS code is 325414 and its SIC code is 2836.